In recent years, a number of transcriptomic biomarkers for identifying FSHD muscle biopsies have been proposed, notably the biopsy-derived 15 gene signature described by Rahimov et al.3, and the 114 gene signature derived from human myoblasts over-expressing DUX4, described by Yao et al.10. This evidence concerns the gene DUX4 and facioscapulohumeral muscular dystrophy.